Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials

BACKGROUND: All currently available SARS-CoV-2 vaccines are administered by intramuscular injection. We aimed to evaluate the safety and immunogenicity of a live-attenuated influenza virus vector-based SARS-CoV-2 vaccine (dNS1-RBD) administered by intranasal spray in healthy adults. METHODS: We did...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Fengcai, Zhuang, Chunlan, Chu, Kai, Zhang, Liang, Zhao, Hui, Huang, Shoujie, Su, Yingying, Lin, Hongyan, Yang, Changlin, Jiang, Hanmin, Zang, Xia, Liu, Donglin, Pan, Hongxing, Hu, Yuemei, Liu, Xiaohui, Chen, Qi, Song, Qiaoqiao, Quan, Jiali, Huang, Zehong, Zhong, Guohua, Chen, Junyu, Han, Jinle, Sun, Hong, Cui, Lunbiao, Li, Jingxin, Chen, Yixin, Zhang, Tianying, Ye, Xiangzhong, Li, Changgui, Wu, Ting, Zhang, Jun, Xia, Ning-Shao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9135375/
https://www.ncbi.nlm.nih.gov/pubmed/35644168
http://dx.doi.org/10.1016/S2213-2600(22)00131-X

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9135375/
https://www.ncbi.nlm.nih.gov/pubmed/35644168
http://dx.doi.org/10.1016/S2213-2600(22)00131-X

Ejemplares similares